Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance Matteo ColinaMicheline KhodeirGabriele Campana Original Research Article Open access 31 January 2024 Pages: 141 - 148
Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System Wenwang LangLian DengMing Ouyang Original Research Article 01 February 2024 Pages: 149 - 162
Effect of Ticagrelor versus Clopidogrel on All-Cause and Cardiovascular Mortality in Acute Coronary Syndrome Patients with Hyperuricemia Shanshan NieYuhang ZhaoGuoping Yang Original Research Article 07 February 2024 Pages: 163 - 174
Safety of Intravenous Push Valproate Compared with Intravenous Piggyback at a Tertiary Academic Medical Center Felicia Y. WangKevin C. McLaughlinRobert E. Dannemiller Original Research Article 16 February 2024 Pages: 175 - 181
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C) Christopher F. BellPriyanka Bobbilithe N3C consortium Original Research Article Open access 20 February 2024 Pages: 183 - 198
Thromboembolic Events Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System (FAERS) Database Xiongwen YangBo YangChengxiao Fu Original Research Article 20 February 2024 Pages: 199 - 207
Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model Ryan ThaliffdeenAnthony YuKaren Rascati Original Research Article 21 February 2024 Pages: 209 - 217
Safety and Efficacy of Biologic Medications and Janus Kinase Inhibitors in Patients with Down Syndrome: A Retrospective Cohort Study Linnea WesterkamLauren PearsonChristopher Sayed Research Letter 19 February 2024 Pages: 219 - 222